10thAnnual

Maximize NIH and DOD Funding

The FreeMind Group is the premier international consulting firm specializing in assisting life science organizations secure non-dilutive funding from US Federal Agencies and Private Foundations

ABOUT US

The FreeMind Group turns non-dilutive funding into a strategic source of funding for life science organizations

Meet us at an upcoming event:

All Upcoming Events →


 
 
 

Experience

Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. Our goal is to assist in maximizing potential to receive funding from non-dilutive sources. We have experience in seeking funding from nearly all NIH Institutes, Department of Defense, NSF, FDA, BARDA, etc., as well as private foundations.

Expertise

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.

Success

FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Awards range from $150,000 to $100,000,000 per project. Our team of experts will assist in making non-dilutive funding a key tool in a long-term sound financial strategy.

Leadership

Ram May-Ron
Ram May-Ron
Managing Partner
Ariel Shatz
Ariel Shatz
Executive Vice President
Ayal Ronen, M.Sc., MBA
Ayal Ronen, M.Sc., MBA
Vice President
Guy Har-Chen, M.Sc., MBA
Guy Har-Chen, M.Sc., MBA
Chief Analyst
Joel Knopf, M.Sc., MBA
Joel Knopf, M.Sc., MBA
Manager of Consulting Services
Merav Geva, Ph.D.
Merav Geva, Ph.D.
Senior Analyst
Sigal Katz, Ph.D.
Sigal Katz, Ph.D.
Senior Analyst
Inna Grodzovski, Ph.D.
Inna Grodzovski, Ph.D.
Senior Analyst

Strategic Partners

  • IIR
  • LSN_logo
  • Medical Device Group
  • Galien Logo
  • OBN
  • wbr
  • advamed
  • elsevier
  • sachs_lge
  • ibf
  • ebd-group
  • onemedplace
  • tvg
  • gtc-bio
  • oregon-bio
  • pa-bio

Services at a Glance

Core Services:

  1. STRATEGIC ASSESSMENT  – Identification and strategy as to applicable funding sources
  2. GRANT PRODUCTION PROCESS – Maximizing chances for a award utilizing a proven strategic approach

 

FreeMind’s professional staff has assisted in attaining funding for R&D activities from all available sources and mechanisms stemming primarily from the National Institutes of Health (NIH) as well as Department of Defense (DoD).

 

We have helped organizations across the life sciences secure funding from these zero-equity sources. We have worked with many academic institutions, as well as industry members from small start-ups through large pharmaceutical companies.

 

 

photodune-368509-successful-manager-xs-1

 
Large Scale Funding

Multidisciplinary grants and contracts available for pre-clinical as well as clinical stage research with budgets of $10 million – $150 million per project


 
💼
SBIR/STTR Grants

Small Business Research and Development grants can be budgeted $150,000 for SBIR/STTR Phase I awards and up to $2 million  for SBIR/STTR Phase II awards.


 
🎯
Targeted Solicitations

UO1s, BAAs, RFPs implemented science and developmental awards with budgets of $3 million – $7 million per project


 
🏆
R21s, and R01s

Basic research, preclinical, and unsolicited grants focusing on early as well as late-stage preclinical research and can be budgeted $1 million – $3 million per project


 

The Process

🔍

Strategic Assessment

This step is designed to provide a robust, long-term, multi-submission strategy for each pipeline project. FreeMind is well versed in the interests, goals and agendas of each NIH Institute. We review the suitability of a proposed project, taking into consideration the significance to public health, innovative factor, strength of research approach, and specific concerns regarding the nature of the project

 

Macro Application Strategy

First, we outline the specific aims and scope of work. Next, the size of the budget is set, and collaborators, subcontractors, and consultants needed for a complete and rounded project are delineated. We devise a timeline and an orderly division of responsibilities in order to facilitate a timely and thorough completion of tasks

Grant production process

Project managers draft comprehensive templates. From this point, the writing effort is combined and is largely based on on-going feedback, comments and edits inserted by the project managers and in response to portions implemented by the client. The iterative review concludes when a well structured scientifically sound application with all items accounted for materializes.

Submission and follow up

After extensive editing and formatting, the application is ready for submission. Post-submission, project managers track the application and when applicable assists in the award negotiation phase. FreeMind closely follows all deadlines for supplementary data, study section reviews, and final decision by the granting agency

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award

Blog

LEARN

Non Dilutive Funding - Non di-lu’-tive Fund-ing

1. funding – financial resources provided to make some project possible; “the National Institute of Health (NIH) provided support for the experiment”

2. non-dilutive funding – the act of financing R&D activity not traded for public securities and/or shares of a commercial entity; “The FreeMind Group assisted in securing non-dilutive funding from the Department of Defense for a Phase II clinical trial”

FreeMind Summer School

Weekly Online Educational Webinars - July 2nd - August 27th, 2014

Participation is FREE of Charge, Registration is Required

Webinars

Syllabus

July 16th, 2014

Watch Recording

Biodefense and Infectious Diseases Non-dilutive Funding

more information

The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA etc. this is a funding force no one in the field can afford to ignore.

July 23rd, 2014

Watch Recording

Funding beyond the SBIR/STTR; RO1s and R21s for Companies

more information

Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources.

R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas RO1s are more suitable for longer programs of up to 5 years, totaling some $3,000,000.

In this webinar FreeMind experts will share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

July 30th, 2014

Watch Recording

Non-Dilutive funding for Non-US applicants

more information

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation we will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

August 6th, 2014

Watch Recording

Cancer Non-dilutive Funding

more information

NIH alone awards roughly $5.8B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.

In the upcoming webinar in the series of summer educational webinars, FreeMind’s VP, Ayal Ronen, will discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for Life Science organizations.

August 13th, 2014

Watch Recording

CNS/PNS Related Non-Dilutive Funding Opportunities

more information

Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

In the webinar in the series of summer educational webinars FreeMind experts will discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.

August 20th, 2014

Watch Recording

Details of a Detailed Budget; Accurately Constructed and well Justified

more information

Assembling a budget for your grant is typically the last item to be addressed. Reason being that the figures you are suggesting must reflect the work you are proposing to complete.

That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of your budget. When comprising the budget one must ensure an accurate completion of the document while adhering to NIH guidelines and stipulations. Items such as indirect costs, sub-contractors, sub-awards, salaries, and even travel expenses must be completed correctly. This becomes increasingly difficult when large and complex applications have several budgets feeding into one.

August 27th, 2014

Watch Recording

Medical Device Non-Dilutive Funding: Trends & Opportunities

more information

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In the webinar in the series of summer educational webinars FreeMind experts will discuss the latest trends at the NIH and the new available funding opportunities with respect to medical devices.

September 3rd, 2014

Watch Recording

Introduction to the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Funding Opportunities

more information

SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics.

SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.

In this webinar we will discuss process for applying, guidelines, key success components and insight into increasing chances for award.

September 10th, 2014

Watch Recording

Registration ins and outs; smooth sailing to an error free submission

more information

Registration is a multi-step process that can take 8 weeks or more and MUST be completed before the submission deadline. Organizations must be registered with the System for Award Management (SAM), Grants.gov and eRA Commons.

The registration process is not sequential. As soon as an organization has obtained its DUNS number, it can begin registering with SAM and then Grants.gov and eRA Commons.

All too often organizations struggle with the registration process. This leads to rejected applications and frustration.

In this webinar FreeMind experts provided a step by step guide to the registration process.

The webinars are designed for first timers as well as seasoned grantees. FreeMind experts will share their insight into various areas of interest as they relate to non-dilutive sources of funding and how to maximize chances for award.

For any inquiries, please email Carla Hamoy: Send Mail

💻

All Webinars are recorded and posted on the FreeMind Group Educational YouTube Channel

JOIN A WEBINAR

FreeMind’s knowledgeable team of expert grant writers share their wisdom on how to maximize chances for award.

Join our mailing list by typing in your email address here:

* Don’t worry, we hate spam as much as you do.

imac

Get in touch with us

For any inquiry or question please contact us by phone or email.

US Office

FreeMind Group
423 Brookline Ave. #124
Boston, MA 02215

Tel: (617) 648-0340
Fax: (617) 904-1767

International Office

FreeMind Group
Hi – Tech Center
Hebrew University
Jerusalem 95702 Israel

Tel: +972 (0)2-6799833
Fax: +972 (0)2-6799834

Contact us using this form


Event produced by FreeMind Group LLC

Non-Dilutive Funding Summit

REGISTER

Where

Nikko Hotel - 222 Mason Street, San Francisco, CA

🕔

When

January 14, 2015

Register Now for the 10th Annual Non-Dilutive Funding Summit

Meeting at a Glance

Join over 400 life science industry leaders in a full day of non-dilutive funding activities at the 10th Annual Non-dilutive Funding Summit, taking place on Wednesday January 14th, 2015 at the Nikko Hotel San Francisco.

The summit is proud to host Dr. Rajesh Ranganathan, the Director of the Office of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS; NIH) who will describe the NINDS and NIH funding opportunities and other resources available to the community that facilitate and enhance biomedical technology development towards commercialization.

See full agenda for details on all the activities during the day.

Who Should Attend

Jet setting Life Science Executives looking to maximize their R&D funding potential through zero-equity sources.

Venue

Participation is FREE of charge, registration is required

Agenda

08:00 - 09:00

Breakfast and Networking

08:00 - 09:00

Pre-Conference Workshop - U'-Mechanisms; Cooperative Agreements

More information

Cooperative Agreements utilizing the U’-Mechanism are designed to allow for a close collaboration with the granting agency. The input and guidance received is invaluable and typically greatly appreciated by the grantee. The associated budgets are also very high. In this workshop we will discuss how to approach the U-Mechanism and ways to maximize chances for award.

Presenters

Joel Knopf M.Sc., MBA

Manager and Senior Consultant, Professional Services, FreeMind Group

Guy Har-Chen, M.Sc., MBA

Chief Analyst, FreeMind Group

09:00 - 10:00

FreeMind Group Presentation

More information

Coming soon

Presenter:

Ram May-Ron, Managing Partner, FreeMind Group

10:00 - 11:00

Keynote Address - New Programs to Support Therapy and Device Discovery and Development in Neurology

More information

The Office of Translational Research (OTR) at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, facilitates the preclinical discovery and development of new therapeutic interventions for neurological disorders. The OTR offers five programs that support the design, implementation, and management of research activities to critical translational challenges in neurology. The programs include: 1) the Anticonvulsant Screening Program (ASP), 2) Blueprint Network (BPN), 3) The Countermeasures Against Chemical Threats Program (CA), 4) Cooperative Research to Enable and Advance Translational Enterprises (CREATE), and 5) The Small Business Innovation Research Program (SBIR). The OTR provides funding (approximately $100 million annually) in grants and resources to industry and university researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Significant emphasis is placed on engaging other stakeholders, such as pharmaceutical, biotechnology, venture capital, and patient advocacy organizations to ensure that projects are adequately de-risked to accelerate downstream investments and to develop much-needed therapies for people suffering from neurological disorders. The keynote talk will provide overiews on these programs and how they can link to successful development outcomes. This will be an excellent opportunity to better understand how to successfully navigate the application process and learn about organizations that have advanced projects using NINDS support. We will also provide information on our funded programs and work with potential interested parties to make the appropriate introductions to our funded investigators.

Presenter:

Dr. Rajesh Ranganathan

Director of the Office of Translational Research at NINDS

Biography

Dr. Rajesh Ranganathan is the Director of the Office of Translational Research at NINDS where he is responsible for leading the Institute’s efforts to more quickly and effectively convert basic and translational research results into new therapeutics. He joined the staff of the NIH in 2010 as the Senior Advisor to the NIH Director for Translational Medicine. Prior to joining the NIH, he spent seven years at the Novartis Institutes for BioMedical Research Inc. as a director in the scientific strategy and portfolio management group; he also founded and led a Global Office of Scientific Education for the Institutes.

The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.www.ninds.nih.gov
ranganathanr
NINDS

11:15- 12:30

Panel Discussion - Industry Leveraging Non-Dilutive Funding

More information

Top Biotech executives share their experience in securing non-dilutive funding from diverse sources such as NIH, NSF, BARDA, and FastForward. Learn of the impact these awards had on overall corporate strategy and long-term growth.

For every $1.00 invested in R&D by the public sector a grantee may expect an additional $8.38 R&D investment by the private sector within 8 years. Milken Institute “Estimating Long-term Economic Returns of NIH on Output in the Bioscience”

Panel Moderator

Ayal Ronen, M.Sc., MBA – Vice President, FreeMind Group

Panelists

Michael P. Allen – President and CEO, EMBOLX

EMBOLX1

Indu Parikh, PhD – President & CSO, BioMarck Pharmaceuticals

Biomarck

Dr. Pablo Villoslada – Founder & Scientific Advisor, Bionure

Bionure1

Meghan Norvell, PhD, MBA – Director Business & Technology Development, nanoMR

nanoMR

12:30 - 1:00

Break

1:00- 2:00

Panel Discussion - Representatives from NIAID, NINDS, BARDA and more discuss Non-Dilutive Sources of Funding available to Industry

More information

listen to representatives from NIAID, NINDS, BARDA and more discuss ways the industry may benefit from non-dilutive funding. In this panel we will discuss how to approach these funding entities and how to maximize chances for award.

Dr Shay Shorer – Director, Office of Clinical Research Affairs (OCRA) – DMID, National Institute of Allergy and Infectious Diseases

NIAID

Dr Gary Disbrow – Acting Director, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures (CBRN), Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services

BARDA

Dr Amir Tamiz – Scientific Program Manager, National Institute of Neurological Disorders and Stroke (NINDS)

NINDS

2:00 - 2:15

Coffee Break

2:15- 3:30

Round Tables - Meet one-on-one with representatives from FreeMind, NIAID, NINDS, BARDA and more discuss Non-Dilutive Sources of Funding relevant to you

More information

Following the panel discussion we will breakout into round table discussions with the panelists where you can discuss in a more relaxed environment specific funding opportunities and gauge the level of interest.

4:00

Meeting Adjourns

Attendee Breakdown

C' Level 67%
V' Level 21%
Academics 7%
Service Providers 5%

2014 Attending Companies

4D Healthware
4PTherapeutics
Abbott
ABL Inc
AC Immune SA
Achaogen
Actogenix
Acuitas Medical Ltd.
ACURE Biotechnology, Inc.
Adiuvo Investment SA
Aduro BioTech, Inc.
AdvaMed
AdvaMed’s Med Tech Conference
AeroDap
Allergan, Inc
Alzeca Biosciences
Amarantus Bioscience
Amarantus Bioscience Holdings
Amarin Pharma Inc.
Ambit Biosciences
AMC Health
Amplyx Pharmaceuticals
Angelica Therapeutics
Aqueduct Neurosciences, Inc.
Arent Fox, LLP
Artax Biopharma Inc
ASE GLOBAL
Asmacure Ltee
AstraZeneca
AtheroNova Inc.
Atlas5D
ATR, LLC
AUST Development
Avacyn Pharmaceuticals, Inc.
Averigon
Barrostat Medical
BioAsset Advisors
BioGenerator
BioMarck Pharmaceuticals
Biomay AG
Biomedical Associates
Biomedical Associates
Bioncotech therapeutics
BIONURE FARMA, S.L.
BioWorld
BioWorld Today/Medical Device Daily
Blueprint Life Science Group
Blueprint Life Science Group
BONESUPPORT AB
Boston Scientific Corporation
Boston Scientific Corporation
Boston University
Boston University
Brain Trust Accelerator Fund
Bridge Technology Foundation
Broadview Ventures
Burrill
C.N.S. Brain Technologies Inc.
C3 International, Inc.
Cary Pharamceuticals
Cederstrom Chiropractic
Cervel Neurotech
Cervel Neurotech Inc.
Cervel Neurotech, Inc
Cervel Neurotech, Inc.
Cevec Pharmaceuticals GmbH, Cologne, Germany
ChelliConnects, LLC
Chiasma
Chiasma Inc
CId Capital Inc.
Clear Catheter Systems
CliniOps, Inc.
Consulate General of Canada
CONSULTANT
Corvida Medical
CPC Scientific
CrystalGenomics, Inc.
CrystalGenomics,Inc
CSA BioTech
CytoMag
DA VOLTERRA
Daugavpils University, Daugavpils, Latvia
Denovo Biomarkers
Digna Biotech
Digna Biotech
Digna Biotech S.L.
Dr Reddy’s Laboratories, Inc
DyAnsys,Inc.
Edinburgh BioQuarter
Editas Medicine
EGEN, Inc
ElMindA
EMACH GROUP
Embolx, Inc.
Ennald Therapeutics
Extend Biopharma
Fast Forward LLC
Fawkes Bio, Inc.
Fibralign Corp.
FireRock Advisors
First Island Capital
Five Crowns Capital
Flip Technologies
FPRT Bio
FreeMind
FreeMind Consultants
Galecto Biotech
GE Ventures
Genmedica Therapeutics
Genogen
Genogen

gIcare pharma inc
GlobalConnectworks
Glysure
GMcK Ventures
Gnosis Bioscience Inc
Go To Market Consulting
GraftWorx
GRM Associates, LLC
GVK BIO
Hall, Estill, Hardwick, Gable, Golden & Nelson
Healthcare and Life Sciences
Hooper Associates
HS Pharmaceticals, LLC
IDSC, LLC
Immatics Biotechnologies GmbH
Immune Targeting Systems (ITS) Limited
ImmusanT
Immusoft
Impax Pharmaceuticals
Indel Therapeutics Inc.
IndiPharm
Industry Canada
Infarct Reduction Technologies Inc
Inflammatory Response Research, Inc.
InfoBionic Inc.
Infusion Innovations, Inc.
Innova Medical
InnovaMedix, Inc.
InSilixa
InSilixa, Inc.
Integrated Meds
Integrium
Inventages
Invest Securities
INVIVOSCIENCES INC
Izumi Biosciences
Jan Medcal, Inc.
Jan Medical
Jan Medical
JHU
Jim Shook Researech, Inc and CATO BioVentures
Johnson & Johnson Innovation Center
JointMetrix Medical, LLC
Juventas Therepeutics, Inc
Karus Therapeutics Ltd
Katan Associates
KNOX Medical Diagnostics
Konzept drug development consulting
Lacerta Technologies GmbH
Lacerta Technologies GmbH
Lasmed Llc
Leaders in Pharmaceutical Business Intelligence
Leopold Grants Consulting
Life Recovery Systems HD, LLC
Life Science Nation
Life Wave Biomedical
Lightlake Therapeutics Inc.
LJV Biotetch / representing Kymab Access Ltd
Loci Control/ Bolt Ventures
logical ventures
Look BIoPharma Consulting
Loupe Strategic Consulting, LLC
LSAN
Lumira Capital
makrocare
MarketSense
Marquant Partners
Massachusetts General Hospital
Maya Clinicals Inc
McDermott Will & Emery
Medical Device Daily
Medical Product Innovation
Medusensor Inc. (formally Sensor Tech)
Memcine Pharmaceuticals
MichBio
Mills & Company Life Science Consultants
Molecular Assemblies, Inc.
Monarch Bay Securities
Montgomery County Dept. Econ Development
Moore Ventures
MRA Associates LLC
MSDx
MSM Protein Technologies
MSM Protein Technologies
Multimeric Biotherapeutics, Inc.
MuriGenics
MVP Capital Partnhers
N/a
N8 Medical
Nabriva Therapeutics AG
Nabriva Therapeutics AG
Nabriva Therapeutics AG
NanoBio
NAS/UIDP
Nervive
NeuProtect Pty Ltd
Neurim Pharma
NEUROCRINE BIOSCIENCES, INC.
NewGen Therapeutics
NIH/NHLBI/DERA/OTAC
NIN
nLife Therapeutics
Nodality
Nordcon Capital
northlea partners
NovaBay Pharmaceuticals
Novartis
NSIP LLC
NSIP LLC
NYU
GERSHON MED TECH

OctreoPharm Sciences GmbH
ODPM
Ogenx Therapeutics
Oligos Etc.
OmniBiome Therapeutics
OmniBiome Therapeutics Inc.
Onciomed, Inc
Oncosynergy
OneBreath, Inc.
Ono Pharma USA Inc
OREGON HEALTH & SCIENCE UNIVERSITY
OREGON HEALTH & SCIENCE UNIVERSITY
Percutaneous Systems, Inc.
PerkinElmer Inc.
Pfizer
Pherin Pharmaceuticals, Inc.
Philips Healthcare
Phosplatin Therapeutics
PIRAMAL LIFE SCIENCES
Pitango Venture Capital
PledPharma AB
POXEL
POXEL SA
Precision Thoracic LLC
Presidio Pharmaceuticals
Pressure BioSciences, Inc.
priaxon ag
ProActive Capital
ProActive Capital
ProActive Capital Group
PROFUSA, Inc.
PROFUSA, Inc.
Prospect Health LLC
Prospect Health LLC
Province of Ontario
PurGenesis Technology
Pushing Innovation
Pushing Innovation
Quimby Heavy Industries
Rapid Relief Solutions, Inc.
Reach Industries
Reflectance Medical Inc.
Regenerate Capital
Respira Therapeutics, Inc.
ReViral Ltd
Rhamnopharma, Inc.
Rizpd
Robert Ferri Partners
ROPAMedics
ROTTAPHARM
rti
s m c
SAJE Pharma, LLC
Salarius Pharmaceuticals
Sanovas, Inc
Sensorion
Shasta BioVentures
Silver Bullet Therapeutics
Silver Bullet Therapeutics, Inc.
SJZ
Solid Ventures
SomaLogic, inc.
Somtherapeutics
Sopharmia Inc
Squirrel Hill Physcial Therapy
SuperVision, Inc.
SutroVax, Inc.
Sutter Health
Suven Life Sciences
Suven Life Sciences Limited
Suven Life Sciences Limited
Taiho Pharmaceutical
Tansia Health
Tansia Health, Inc
Targazyme Inc
Targeted Medical Pharma, Inc.
Teva
The ALS Emergency Treatment Fund
The Conafay Group
The Jobson Group, Inc.
TheraJect, Inc.
Thomson Reuters/BioWorld
TONIX Pharmaceuticals, Inc.
Tosk, Inc.
Tufts University
Turnkey Healthcare Management Inc
UCSF
UCSF
UCSF/UCLA
UNICONNECT
University of California, San Francisco
University of Miami
University of New Mexico School of Medicine
Valley Fever Solutions
Vanguard Therapeutics, Inc.
vaxess technologies, Inc.
Velocity Pharmaceutical Development
Velomedix
Velomedix Inc
Verve Medical Inc
Vesiflo
viDA Therapeutics
Vigilant Biosciences, Inc.
Virometix AG
Vital Therapies
W. H. Coulter Foundation
Washington Biotechnology & Biomedical Association
WI Harper Group
WI Harper Group
WinSanTor
Yale university

Blog Categories

Join our Mailing List

* Don't worry, we hate spam as much as you do.
Contact us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Questions, issues or concerns? I'd love to help you!

Click ENTER to chat